Spyre Therapeutics
SYRE
23 hedge funds and large institutions have $26.6M invested in Spyre Therapeutics in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
41.22% more ownership
Funds ownership: 0% → 41.22% (+41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$10.6M |
| 2 |
O
OrbiMed
New York
|
+$10.4M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$4.02M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.1M |
Top Sellers
SYRE Hedge Fund Activity: Q2 2016 in Review
23 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2016, worth a combined $26.6M.
Buyers outnumbered sellers: 23 funds opened new SYRE positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $10.6M.
- 23 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $26.6M of Spyre Therapeutics stock for Q2 2016.
- 23 funds opened new Spyre Therapeutics positions in Q2 2016 and 0 closed out, a net change of +23 holders.
- The largest Spyre Therapeutics buyer in Q2 2016 was Jennison Associates, an estimated $10.6M added.
Based on aggregated 13F filings for Q2 2016.